BIRC2 and acute lymphoblastic leukemia: In a first step, we assessed the sensitivity of B‐ and T‐ALL cell lines to non‐selective IAP inhibitors, including the multivalent SM LBW242 (or its orthologue LCL161; Sharma et al, 2006) and BV6 (Varfolomeev et al, 2007), which target several IAP family members, including cIAP‐1/2 and XIAP.